Supplementary material

Supplementary Figure 1: The FluidCrystal® drug delivery system[1–4]



Supplementary Figure 2: Overview of AcroQoL, TSQM, SIAQ and PSS



ACROINNOVA 1 and ACROINNOVA 2 were not powered to assess changes in acromegaly symptom severity using the ACROQoL, TSQM, SIAQ or PSS. *A 1–5 Likert scale measuring the frequency of occurrence (always, most of the time, sometimes, rarely, or never) or the degree of agreement with the items (completely agree, moderately agree, neither agree nor disagree, moderately disagree or completely disagree); †The psychological domain is subdivided into physical appearance and impact of the disease on personal relationships; ‡The pre-injection module contains the following domains: general feelings about injections; self-confidence about giving self-injections; and satisfaction with the current way of taking medication; §The post-injection module contains the pre-injection module domains and the following additional domains: self-image; injection site reactions; ease of use of the self-injection device; and satisfaction with self-injection. ATG, Autogel; LAR, long-acting repeatable; QoL, quality of life.

Supplementary Table 1: Summary of AEs reported in ACROINNOVA 2

n (%)	Directly enrolled (N=81)	Prior-CAM2029 (N=36)	Prior-placebo (N=18)	Overall (N=135)
Any AE	56 (69.1)	34 (94.4)	12 (66.7)	102 (75.6)
Any CAM2029-related AE	39 (48.1)	23 (63.9)	12 (66.7)	74 (54.8)
Any AE of Grade				
1	51 (63.0)	32 (88.9)	11 (61.1)	94 (69.6)
2	22 (27.2)	19 (52.8)	6 (33.3)	47 (34.8)
3	9 (11.1)	7 (19.4)	1 (5.6)	17 (12.6)
Any SAE	6 (7.4)	8 (22.2)	1 (5.6)	15 (11.1)
Any CAM2029-related SAE	0	0	1 (5.6)*	1 (0.7)
Any AE leading to discontinuation of CAM2029	2 (2.5)	0	0	2 (1.5)
Any AE leading to dose reduction	0	0	1 (5.6)	1 (0.7)
Any injection-site AE†	32 (39.5)	19 (52.8)	9 (50.0)	60 (44.4)

AEs refer to TEAEs. Only TEAEs and SAEs reported from the first administration of CAM2029 until week 52 are included. *Cholelithiasis (Grade 2; resolved); †AEs included injection site bruising, dermatitis, discomfort, erythema, extravasation, haematoma, haemorrhage, hypertrophy, inflammation, induration, mass, nodule, oedema, pain, pruritus, reaction and swelling. AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

References

1. Tiberg F *et al. Chem Lett* 2012;41:1090–2.
2. Tiberg F, Johnsson M. *J Drug Deliv Sci Technol* 2011;21:101–9.
3. Engstedt J *et al. Colloids Surf B Biointerfaces* 2024:239:113955.
4. Tiberg F *et al. Br J Clin Pharmacol* 2015;80:460–72.
5. Badia X *et al. Health Qual Life Outcomes* 2004;2:13.
6. Atkinson MJ *et al. Health Qual Life Outcomes* 2004;2:12.
7. Keininger D, Coteur G. *Health Qual Life Outcomes* 2011;9:2.